Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series

Matteo S. Carlino, Vito Vanella, Christina Girgis, Diana Giannarelli, Alex Guminski, Lucia Festino, Richard F. Kefford, Alexander M. Menzies, Georgina V. Long, Paolo Antonio Ascierto

Research output: Contribution to journalArticlepeer-review

Abstract

Background:It is unknown whether melanoma patients achieving complete response (CR) with targeted therapy can safely discontinue treatment.Methods:All patients treated with BRAF/MEK inhibitors achieving CR and ceasing treatment before progression were identified. Clinical data at treatment initiation, cessation and progression were examined.Results:A total of 12 eligible patients were identified, with median follow-up of 16 months, of whom 6 (50%) recurred at a median of 6.6 months after treatment cessation. One patient lost to follow-up until presentation with symptomatic recurrence was the only relapser to die. At relapse, the remaining five patients had an LDH <1.2 times ULN, four were ECOG 0 and one ECOG 1. Baseline characteristics and time to CR and to discontinuation did not influence the rate of relapse.Conclusions:A large proportion of patients achieving CR with BRAF/MEK inhibitors relapse after treatment cessation. The optimal treatment duration in such patients is unclear, particularly where alternative treatments are available.British Journal of Cancer advance online publication 6 October 2016; doi:10.1038/bjc.2016.321 www.bjcancer.com.

Original languageEnglish
JournalBritish Journal of Cancer
DOIs
Publication statusAccepted/In press - Oct 6 2016

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series'. Together they form a unique fingerprint.

Cite this